iLIVER最新文献

{"title":"Multiomic predictors for regression of cirrhosis: Clinical implications and future directions","authors":"Binghua Li, Decai Yu","doi":"10.1016/j.iliver.2024.100116","DOIUrl":"10.1016/j.iliver.2024.100116","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100116"},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142426498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network pharmacology and single-cell transcriptomic analysis with molecular docking to elucidate the potential compounds and targets of Polygonum cuspidatum Sieb.et Zucc. for hepatocellular carcinoma","authors":"Wenze Wu ,&nbsp;Yuzhu Shi ,&nbsp;Yongzi Wu ,&nbsp;Rui Zhang ,&nbsp;Xinyan Wu ,&nbsp;Weidi Zhao ,&nbsp;Zhiyuan Chen ,&nbsp;Gang Ye","doi":"10.1016/j.iliver.2024.100115","DOIUrl":"10.1016/j.iliver.2024.100115","url":null,"abstract":"<div><h3>Background and aims</h3><p><em>Polygonum cuspidatum</em> Sieb.et Zucc. (<em>P. cuspidatum</em>) and its active components have been clinically proven to have anti-hepatocellular carcinoma effects. However, the potential targets of <em>P. cuspidatum</em> for these effects have not yet been revealed.</p></div><div><h3>Methods</h3><p>We used network pharmacology and single-cell transcriptomic analysis with molecular docking to elucidate the active components and targets of <em>P. cuspidatum</em> for hepatocellular carcinoma.</p></div><div><h3>Results</h3><p>CDK1, ESR1, HSP90A11, and MAPK1 were shown to be the key targets of <em>P. cuspidatum</em> for hepatocellular carcinoma. <em>P. cuspidatum</em> was found to be likely correlated with the improved abnormal expression of CDK1 and ESR1 and the poor prognosis of HSP90AA1 and MAPK1. CDK1 was identified as the most potential anti-hepatocellular carcinoma target of <em>P. cuspidatum</em>. Among the active components of <em>P. cuspidatum</em>, physcion diglucoside was found to have the most potential to treat hepatocellular carcinoma by targeting CDK1.</p></div><div><h3>Conclusion</h3><p>Our study provides novel insights into the anti-hepatocellular carcinoma pharmacological effects of <em>P. cuspidatum</em>, which could serve as a scientific basis for its development as a medicinal resource and the targeting of CDK1 for hepatocellular carcinoma treatment.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100115"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000409/pdfft?md5=11fd39f142c9e35b0e9dd563005a3e5a&pid=1-s2.0-S2772947824000409-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial chemoembolization plus radiofrequency ablation: One of the effective interventions for hepatocellular carcinoma","authors":"Yong Xie,&nbsp;Jian Wang,&nbsp;Yinghua Zou","doi":"10.1016/j.iliver.2024.100114","DOIUrl":"10.1016/j.iliver.2024.100114","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100114"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000392/pdfft?md5=872f44ce832e9d7fb0cf35da0ff3d221&pid=1-s2.0-S2772947824000392-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting hepatocellular carcinoma growth and metabolism: A synergistic approach with para-toluenesulfonamide and radiofrequency ablation","authors":"Na Liu ,&nbsp;Jianzeng Zhang ,&nbsp;Jiaojiao Wu ,&nbsp;Fan Feng ,&nbsp;Yantao Chai ,&nbsp;Yongwu Li ,&nbsp;Bo Liu","doi":"10.1016/j.iliver.2024.100111","DOIUrl":"10.1016/j.iliver.2024.100111","url":null,"abstract":"<div><h3>Background and aims</h3><p>Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal forms of cancer, posing challenges to standard treatment methods. Radiofrequency ablation (RFA) has emerged as a valuable technique for the local control of advanced HCC, especially in cases unsuitable for surgical resection. Para-toluenesulfonamide (PTS) has demonstrated antitumor properties in various cancers, yet its efficacy against HCC remains underexplored. The present study aims to investigate the therapeutic potential of PTS in HCC and examine potential synergistic effects with RFA.</p></div><div><h3>Methods</h3><p>PTS was injected directly into subcutaneous tumor tissues and its effects on cell survival, gene expression, and metabolic activity in HCC cells were evaluated. The effect of PTS and RFA in combination on HCC growth was examined using a nude mouse model of subcutaneous HCC. Data were visualized using heat maps.</p></div><div><h3>Results</h3><p>PTS inhibited the survival of HCC cells in a dose-dependent manner, modulating the expression of key genes related to cell survival, apoptosis, epithelial–mesenchymal transition, and proliferation. The combination of PTS and RFA markedly enhanced the inhibition of HCC tumor growth and induced alterations in cellular metabolism.</p></div><div><h3>Conclusion</h3><p>Combining PTS and RFA may be a promising approach to improve the efficacy of HCC treatment.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100111"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000367/pdfft?md5=b0e8499504bb732be1b53d5b3ef270e3&pid=1-s2.0-S2772947824000367-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the epidemiology of metabolic dysfunction-associated liver cancer: Insights from mixed etiologies, regional variations, and gender disparities","authors":"Gong Feng ,&nbsp;Ya-Fei Fan ,&nbsp;Ru-Xin Li ,&nbsp;Giovanni Targher ,&nbsp;Christopher D. Byrne ,&nbsp;Ming-Hua Zheng","doi":"10.1016/j.iliver.2024.100113","DOIUrl":"10.1016/j.iliver.2024.100113","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100113"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000380/pdfft?md5=900c268f6fb3052db25147560b9aa2ec&pid=1-s2.0-S2772947824000380-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic treatment in unresectable hepatocellular carcinoma: The most concerns","authors":"Jian-Hong Zhong,&nbsp;Kang Chen,&nbsp;Ze Su,&nbsp;Shao-Ping Liu,&nbsp;Fan-Jian Zeng,&nbsp;Lin Ye,&nbsp;the GUIDANCE investigators","doi":"10.1016/j.iliver.2024.100112","DOIUrl":"10.1016/j.iliver.2024.100112","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100112"},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000379/pdfft?md5=520af061d7f9f40ec565cf72ac9acec5&pid=1-s2.0-S2772947824000379-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimising postoperative surveillance for hepatocellular carcinoma: Beyond histological predictors","authors":"Jiahao Xu ,&nbsp;Lihui Gu ,&nbsp;Tian Yang","doi":"10.1016/j.iliver.2024.100110","DOIUrl":"10.1016/j.iliver.2024.100110","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100110"},"PeriodicalIF":0.0,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000355/pdfft?md5=08e6e95a553cdb667d6ca485e4835264&pid=1-s2.0-S2772947824000355-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic research on MASLD: New insights into cardiovascular disease and cancer risk","authors":"Ming Yang,&nbsp;Juan Liu","doi":"10.1016/j.iliver.2024.100108","DOIUrl":"10.1016/j.iliver.2024.100108","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100108"},"PeriodicalIF":0.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000331/pdfft?md5=45e308ef2f4897a9eff0d22fcfb13eeb&pid=1-s2.0-S2772947824000331-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody","authors":"Shichuan Tang ,&nbsp;Tingfeng Huang ,&nbsp;Cong Luo ,&nbsp;Jun Fu ,&nbsp;Kailing Zhang ,&nbsp;Qingjing Chen ,&nbsp;Jie Kong ,&nbsp;Jianxi Zhang ,&nbsp;Zhenghong Sun ,&nbsp;Yongkang Diao ,&nbsp;Kongying Lin ,&nbsp;Yongyi Zeng","doi":"10.1016/j.iliver.2024.100109","DOIUrl":"10.1016/j.iliver.2024.100109","url":null,"abstract":"<div><h3>Background</h3><p>Tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies in combination provide survival benefits for patients with unresectable hepatocellular carcinoma (uHCC). However, the tool used to determine which patients likely benefit most from this treatment strategy has not been reported. We sought to develop a prognostic scoring system based on tumor burden score (TBS) and alpha-fetoprotein (AFP) to predict the long-term prognosis of uHCC treated with TKIs and anti-PD-1 antibodies.</p></div><div><h3>Methods</h3><p>Data on patients with uHCC treated with TKIs and anti-PD-1 antibodies from multiple centers were collected. The prognostic accuracy of TBS, AFP, Barcelona Clinic Liver Cancer (BCLC), and CTA (Combined TBS and AFP) for 2-year progression-free survival (PFS) and overall survival (OS) was evaluated.</p></div><div><h3>Results</h3><p>Overall, 278 patients with uHCC treated with TKIs and anti-PD-1 antibodies were enrolled, including 48 BCLC-B and 230 BCLC-C HCC patients. CTA (AUC = 0.721 and 0.683) outperformed TBS (AUC = 0.680 and 0.621), AFP (AUC = 0.606 and 0.594), and BCLC staging (AUC = 0.551 and 0.555) in predicting PFS and OS. The 2-year PFS and OS for low CTA (low TBS/low AFP) were 65.7% and 94.4%, respectively, which were significantly higher than 21.6% and 44.9% (<em>p</em> &lt; 0.001 and <em>p</em> = 0.002), respectively, for intermediate CTA (low TBS/high AFP or high TBS/low AFP) and 8.7% and 12.1% (both <em>p</em> &lt; 0.001), respectively, for high CTA (high TBS/high AFP). Multivariable Cox regression analysis indicated that CTA grading was an independent prognostic factor for PFS and OS (referent: low CTA; intermediate CTA, HR 2.87 and 7.17; high CTA, HR 5.52 and 10.31, respectively).</p></div><div><h3>Conclusions</h3><p>CTA grading is an accurate tool for stratifying the prognosis of uHCC treated with TKIs and anti-PD-1 antibodies and may help determine which patients may benefit more from this treatment strategy.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100109"},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000343/pdfft?md5=6af753a448301ae70ed3eddae4d63605&pid=1-s2.0-S2772947824000343-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum IP-10 increase correlated with PEG-IFNα response in nucleot(s)ide analogs-treated patients with chronic hepatitis B","authors":"Wen-Xin Wang ,&nbsp;Xiaoyan Li ,&nbsp;Xue-Yuan Jin ,&nbsp;Rui Jia ,&nbsp;Hong-Min Wang ,&nbsp;Shuang-Nan Zhou ,&nbsp;Xin Zhang ,&nbsp;Ying-Ying Gao ,&nbsp;Fu-Sheng Wang ,&nbsp;Junliang Fu","doi":"10.1016/j.iliver.2024.100107","DOIUrl":"10.1016/j.iliver.2024.100107","url":null,"abstract":"<div><h3>Background and aims</h3><p>To investigate the association between serum IP-10 and HBsAg levels in chronic hepatitis B (CHB) patients previously treated with nucleot(s)ide analogs (NAs) followed by combined treatment with an NA and pegylated interferon alpha (PEG-IFNα).</p></div><div><h3>Methods</h3><p>Ninety-nine patients with serum levels of HBsAg &lt;3000 IU/mL and HBV DNA &lt;20 IU/mL who received prior NA treatment were enrolled. Participants were administered either NA monotherapy (NA group) or combination therapy with PEG-IFNα (Add-on group). Laboratory indicators and IP-10 levels were assessed in serial peripheral blood samples collected at 12- and 24-week intervals. The outcome of this study was a loss or &gt;1 log₁₀ IU/mL decline in serum HBsAg.</p></div><div><h3>Results</h3><p>After 48 weeks of antiviral therapy, none of the 27 NA group patients and 15 of the 72 Add-on group patients achieved HBsAg loss. Baseline serum HBsAg and IP-10 levels were equivalent across both groups. The combination treatment led to a decrease in serum HBsAg levels and an early increase in IP-10 levels. Furthermore, a moderate increase in IP-10 levels at weeks 12 or 24 was correlated with loss and decline of HBsAg in the Add-on group. Receiver operating characteristic curve and regression analyses demonstrated that a moderate increase in serum IP-10 levels at weeks 12 or 24 was predictive of HBsAg loss and decline in the Add-on group (<em>p</em> &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>An early and moderate increase in the serum IP-10 level was correlated with responses to PEG-IFNα among patients with CHB treated with NAs.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100107"},"PeriodicalIF":0.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277294782400032X/pdfft?md5=05062282b65b7d860c2f3674209bd868&pid=1-s2.0-S277294782400032X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}